JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB223578

Anti-PTGIS/PGIS antibody

Be the first to review this product! Submit a review

|

(1 Publication)

Goat Polyclonal PTGIS/PGIS antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human PTGIS aa 200-300.

View Alternative Names

CYP8, CYP8A1, PTGIS, Prostacyclin synthase, Hydroperoxy icosatetraenoate dehydratase, Prostaglandin I2 synthase

1 Images
Western blot - Anti-PTGIS/PGIS antibody (AB223578)
  • WB

Supplier Data

Western blot - Anti-PTGIS/PGIS antibody (AB223578)

Primary incubation was 1 hour.

All lanes:

Western blot - Anti-PTGIS/PGIS antibody (ab223578) at 0.5 µg/mL

Lane 1:

Human lung lysate (in RIPA buffer) at 35 µg

Lane 2:

Human ovary lysate (in RIPA buffer) at 35 µg

Predicted band size: 57 kDa

Observed band size: 55 kDa

true

Key facts

Host species

Goat

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

Synthetic Peptide within Human PTGIS aa 200-300. The exact immunogen used to generate this antibody is proprietary information.

Q16647

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "0.5-1.5 µg/mL", "WB-species-notes": "<p>1 hour primary incubation is recommended for this product.</p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Purification notes
ab223578 was purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Storage buffer
pH: 7.3 Preservative: 0.02% Sodium azide Constituents: Tris buffered saline, 0.5% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein PTGIS also known as prostacyclin synthase (PGIS) is an enzyme involved in the conversion of prostaglandin H2 (PGH2) to prostacyclin (PGI2) a member of the prostaglandin family. It has a molecular mass of approximately 56 kDa. PTGIS is mainly expressed in vascular endothelial cells as well as in other tissues including heart kidney and lung. The protein is important for various physiological functions due to its enzymatic role in prostacyclin synthesis.
Biological function summary

PTGIS plays a role in vasodilation and inhibiting platelet aggregation. Prostacyclin the product of PTGIS activity functions as a potent vasodilator and inhibitor of platelet activation which are key processes for maintaining vascular health. PTGIS does not form part of a larger protein complex but works independently to generate its product PGI2. By performing these roles PTGIS contributes significantly to cardiovascular homeostasis.

Pathways

PTGIS is an important component of the prostaglandin biosynthesis pathway. This pathway is important for the formation of several types of prostaglandins which are involved in various aspects of inflammation and vascular function. PTGIS connects closely with cyclooxygenase (COX) enzymes specifically COX-1 and COX-2 which generate PGH2 from arachidonic acid. The interaction with COX enzymes is necessary for the effective production of prostacyclin.

PTGIS has implications in thrombotic diseases and pulmonary hypertension. The enzyme's role in inhibiting platelet aggregation makes it relevant in conditions where clot formation is a risk such as cardiovascular disorders. Its relation to pulmonary hypertension involves dysregulation of prostacyclin production which affects blood pressure in lung arteries. Additionally interactions with proteins like thromboxane synthase which counteracts the effects of prostacyclin are important for understanding the balance between factors promoting and inhibiting thrombosis in these conditions.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Catalyzes the biosynthesis and metabolism of eicosanoids. Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2), a potent mediator of vasodilation and inhibitor of platelet aggregation (PubMed : 12372404, PubMed : 15115769, PubMed : 18032380, PubMed : 25623425). Additionally, displays dehydratase activity, toward hydroperoxyeicosatetraenoates (HPETEs), especially toward (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate (15(S)-HPETE) (PubMed : 17459323).
See full target information PTGIS

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Poultry science 103:103435 PubMed38232620

2024

Betaine supplementation alleviates corticosterone-induced hepatic cholesterol accumulation through epigenetic modulation of HMGCR and CYP7A1 genes in laying hens.

Applications

Unspecified application

Species

Unspecified reactive species

Yulin Wu,Mengwei Zhang,Fanchi Meng,Kunpeng Ren,Ding Li,Xugang Luo,Yun Hu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com